We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-4.93%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$98.8B
AUM Growth
-$3.4B
Cap. Flow
+$2.69B
Cap. Flow %
2.72%
Top 10 Hldgs %
24.29%
Holding
4,219
New
200
Increased
1,781
Reduced
1,776
Closed
283
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IBDV icon
2601
iShares iBonds Dec 2030 Term Corporate ETF
IBDV
$3.31B
$712K ﹤0.01%
35,119
+142
+0.4% +$3.05K
OCSL icon
2602
Oaktree Specialty Lending
OCSL
$1.15B
$711K ﹤0.01%
39,522
-2,367
-6% -$48.2K
CYTK icon
2603
Cytokinetics
CYTK
$10.2B
$710K ﹤0.01%
14,656
-1,025
-7% -$49.3K
LRN icon
2604
Stride
LRN
$3.27B
$710K ﹤0.01%
16,882
+6,857
+68% +$276K
ERIE icon
2605
Erie Indemnity
ERIE
$13.5B
$706K ﹤0.01%
3,176
-364
-10% -$76.7K
AUY
2606
DELISTED
Yamana Gold, Inc.
AUY
$705K ﹤0.01%
155,595
+45,577
+41% +$211K
GDL
2607
GDL Fund
GDL
$91.7M
$704K ﹤0.01%
88,868
+194
+0.2% +$1.58K
LI icon
2608
Li Auto
LI
$12B
$703K ﹤0.01%
30,556
-4,244
-12% -$132K
FAAR icon
2609
First Trust Alternative Absolute Return Strategy ETF
FAAR
$197M
$702K ﹤0.01%
22,600
-5,860
-21% -$189K
GBDC icon
2610
Golub Capital BDC
GBDC
$3.48B
$702K ﹤0.01%
56,650
-2,879
-5% -$39.2K
KRTX
2611
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$701K ﹤0.01%
3,117
-33
-1% -$6.68K
QVMT
2612
Invesco S&P 500 Concentrated QVM ETF
QVMT
$138M
$700K ﹤0.01%
19,344
-15,343
-44% -$623K
PTON icon
2613
Peloton Interactive
PTON
$2.44B
$699K ﹤0.01%
100,799
-2,595
-3% -$26.4K
ATRA icon
2614
Atara Biotherapeutics
ATRA
$83.1M
$697K ﹤0.01%
7,374
+4,765
+183% +$535K
NUBD icon
2615
Nuveen ESG US Aggregate Bond ETF
NUBD
$466M
$697K ﹤0.01%
32,171
+1,860
+6% +$42.3K
GSG icon
2616
iShares S&P GSCI Commodity-Indexed Trust
GSG
$932M
$695K ﹤0.01%
33,779
+1,200
+4% +$26.4K
USAC icon
2617
USA Compression Partners
USAC
$3.84B
$695K ﹤0.01%
39,966
+7,597
+23% +$134K
CLPR
2618
Clipper Realty
CLPR
$53M
$694K ﹤0.01%
99,542
-16,939
-15% -$142K
MFIC icon
2619
MidCap Financial Investment
MFIC
$811M
$694K ﹤0.01%
67,890
+8,451
+14% +$103K
TCBI icon
2620
Texas Capital Bancshares
TCBI
$4.38B
$694K ﹤0.01%
11,754
-5,861
-33% -$347K
VKQ icon
2621
Invesco Municipal Trust
VKQ
$545M
$694K ﹤0.01%
75,964
+898
+1% +$9.13K
MLP icon
2622
Maui Land & Pineapple Co
MLP
$310M
$693K ﹤0.01%
75,250
-2
-0% -$19
PGJ icon
2623
Invesco Golden Dragon China ETF
PGJ
$93.2M
$692K ﹤0.01%
27,281
+7,771
+40% +$228K
PJUL icon
2624
Innovator US Equity Power Buffer ETF July
PJUL
$1.29B
$692K ﹤0.01%
+24,180
New +$729K
AFRM icon
2625
Affirm
AFRM
$26.2B
$691K ﹤0.01%
36,837
-6,094
-14% -$159K

Similar funds

Raymond James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Raymond James & Associates held 4,219 positions worth $98.8B, down 3.3% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2022 filing shows 200 new, 1,781 increased, 1,776 reduced and 283 closed positions. Its largest new stake was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M. The largest sale was iShares Core 1-5 Year USD Bond ETF, an estimated $255M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q3 2022 buy was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q3 2022, an estimated $620M increase.
  • Raymond James & Associates's biggest Q3 2022 reduction was iShares Core 1-5 Year USD Bond ETF, cutting an estimated $255M.
  • Raymond James & Associates fully exited CDK Global, Inc. in Q3 2022, selling an estimated $36M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $98.8B portfolio in Q3 2022.
  • Raymond James & Associates opened 200 new positions and closed 283 in Q3 2022.
  • Raymond James & Associates's portfolio value fell 3.3% quarter-over-quarter to $98.8B.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.